Quick Answer
Bolt Biotherapeutics, Inc. reported R&D Expense of $28.53 million for fiscal year 2025.
Bolt Biotherapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $28.53M | -50.4% |
| 2024 | $57.47M | -6.6% |
| 2023 | $61.54M | -15.8% |
| 2022 | $73.12M | -3.3% |
| 2021 | $75.66M | +87.5% |
| 2020 | $40.36M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.54M | -52.6% | -12.8% |
| June 30, 2025 | $7.50M | -51.4% | -21.2% |
| March 31, 2025 | $9.51M | -42.5% | -31.0% |
| September 30, 2024 | $13.79M | -7.8% | -10.7% |
| June 30, 2024 | $15.43M | -1.3% | -6.6% |
| March 31, 2024 | $16.53M | +13.0% | +10.6% |
| September 30, 2023 | $14.95M | -21.2% | -4.4% |
| June 30, 2023 | $15.64M | -17.3% | +7.0% |
- Bolt Biotherapeutics, Inc. showed a decrease of -50.4% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Bolt Biotherapeutics, Inc.’s r&d expense has declined by 29.3% (from $40.36 million to $28.53 million).
- The most recent figure is from Bolt Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: